Prostate cancer markers: An update (Review)

Srinivas Pentyala, Terry Whyard, Sahana Pentyala, John Muller, John Pfail, Sunjit Parmar, Carlos G. Helguero, Sardar Khan

Research output: Contribution to journalReview articlepeer-review

40 Scopus citations


As the most common noncutaneous malignancy in American men, prostate cancer currently accounts for 29% of all diagnosed cancers, and ranks second as the cause of cancer fatality in American men. Prostatic cancer is rarely symptomatic early in its course and therefore disease presentation often implies local extension or even metastatic disease. Thus, it is extremely critical to detect and diagnose prostate cancer in its earliest stages, often prior to the presentation of symptoms. Three of the most common techniques used to detect prostate cancer are the digital rectal exam, the transrectal ultrasound, and the use of biomarkers. This review presents an update regarding the field of prostate cancer biomarkers and comments on future biomarkers. Although there is not a lack of research in the field of prostate cancer biomarkers, the discovery of a novel biomarker that may have the advantage of being more specific and effective warrants future scientific inquiry.

Original languageEnglish
Pages (from-to)263-268
Number of pages6
JournalBiomedical Reports
Issue number3
StatePublished - Mar 2016
Externally publishedYes


  • Biomarkers
  • Gleason scores
  • Metastasis
  • Prostate cancer
  • Prostatectomy


Dive into the research topics of 'Prostate cancer markers: An update (Review)'. Together they form a unique fingerprint.

Cite this